Cost-effectiveness analysis of adjuvant hormonal treatments for women with postmenopausal hormone-receptor positive early breast cancer in the Korean context

Journal of Breast Cancer

Volumn 13, Issue 3, 2010, Pages 286-298

  Lee, Hye Jae ^a   Lee, Tae Jin ^a   Yang, Bong Min ^a   Min, Junwon ^a  

^a Seoul National University   (South Korea)

Author keywords

Anastrozole; Cost benefit analysis; Costs and cost analysis; Letrozole

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED CANCER; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HIDDEN MARKOV MODEL; HIP FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; QUALITY OF LIFE; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 78249243845     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2010.13.3.286     Document Type: Article

References (48)

1. Korean Breast Cancer Society. Breast Cancer Facts and Figures. Seoul: Korean Breast Cancer Society; 2008. p.5.
2. National Health Insurance Corporation, Health Insurance Review and Assessment Service. National Health Insurance Statistical Yearbook 2007. Seoul: National Health Insurance Corporation, Health Insurance Review and Assessment Service; 2008. p.398.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
4. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
5. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
6. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
7. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
8. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
9. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76.
10. Drummond MF. Principles of Economic Appraisal in Health Care. New York: Oxford University Press; 1980.
11. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press; 2005.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
13. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
14. Yang JJ. Cost-Effectiveness Analysis of Post-Operative Adjuvant Use of Tamoxifen and Breast Cancer. Seoul: Graduate School of Public Health, Seoul National University; 2007.
15. Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002;8:81-7.
16. Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys 2001;51:74-80.
17. Haylock BJ, Coppin CM, Jackson J, Basco VE, Wilson KS. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiat Oncol Biol Phys 2000;46:355-62.
18. Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000;18:1696-708.
19. Kamby C, Sengeløv L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997; 45:181-92.
20. Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994;12: 2071-7.
21. Toonkel LM, Fix I, Jacobson LH, Wallach CB. The significance of local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 1983;9:33-9.
22. Koning C, Hart G. Long-term follow-up of a randomized trial on adjuvant chemotherapy and hormonal therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998;41:397-400.
23. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 2008;9:171-83.
24. Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 2008;108: 375-87.
25. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
26. Lee SE, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Contemporary trends of endometrial cancer in Korean women. Korean J Gynecol Oncol 2005;16:215-20.
27. Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004;91:424-8.
28. Jee SH, Pastor-Barriuso R, Appel LJ, Suh I, Miller ER 3rd, Guallar E. Body mass index and incident ischemic heart disease in South Korean men and women. Am J Epidemiol 2005;162:42-8.
29. Lim S, Koo BK, Lee EJ, Park JH, Kim MH, Shin KH, et al. Incidence of hip fractures in Korea. J Bone Miner Metab 2008;26:400-5.
30. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726-33.
31. Statistics of mortality by cause. Korean Statistical Information Services. http://www.kosis.kr/. accessed Oct 1st, 2009.
32. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health 2008;11: 213-20.
33. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007;105 Suppl 1:19-29.
34. Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health 2004;94:2104-11.
35. Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-61.
36. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
37. Roger VL, Jacobsen SJ, Weston SA, Goraya TY, Killian J, Reeder GS, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 2002;136:341-8.
38. Empana JP, Dargent-Molina P, Bréart G; EPIDOS Group. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004;52:685-90.
39. Korean Breast Cancer Society, Korean Medical Guideline Information Center. 2008 Clinical Practice Guideline for Breast Cancer. 3rd ed. Seoul: Korean Breast Cancer Society; 2008.
40. Statistics of price index by year. Korean Statistical Information Services. http://www.kosis.kr/. accessed Oct 1st, 2009.
41. Sorensen SV, Brown R, Benedict A, Flood E, Revicki D. Patientrated utilities in postmenopausal Early Breast Cancer (EBC): a cross-country comparison. Contributed Podium Presentations. Value Health 2004;7:637-57. abstract #QL4.
42. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer 2007;97:152-61.
43. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42.
44. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41.
45. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with earlystage estrogen receptor-positive breast cancer. Cancer 2004;101: 1311-22.
46. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11: iii-iv, ix-xi, 1-134.
47. Korea Institute for Health and Social Affairs. Korean Utility Weights for Major Chronic Diseases. Policy Report 2008-06. Seoul: Korea Institute for Health and Social Affairs; 2008.
48. Ahn SH, Park BW, Noh DY, Nam SJ, Lee ES, Lee MK, et al. Healthrelated quality of life in disease-free survivors of breast cancer with the general population. Ann Oncol 2007;18:173-82.